Ubiquinol to See if It Reduces Fatigue for Adults Using GLP-1 Weight-Loss Meds

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests whether ubiquinol 100 mg taken daily for 9 months can reduce fatigue and help maintain muscle strength in adults aged 30–65 who are starting or have recently started a GLP-1 weight-management therapy (Wegovy or Mounjaro). Participants will take the supplement or a matching placebo every day and have four home visits for measurements, blood samples, and a simple sit-to-stand test. They will also participate in monthly virtual visits to monitor progress. The study aims to compare fatigue levels and muscle strength between the ubiquinol and placebo groups. Enrollment requires smartphone access, English proficiency, and active participation in the weight-management treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 30-65 years
* Body mass index \>27kg/m2 and \<35 kg/m2
* Currently initiating, or has initiated within the preceding 16 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication of weight management.
* Is physically mobile and able to complete at least one sit to stand movements
* Owns a smartphone (iOS 15.6 or later, Android 9 or later) and is willing and able to install the SANNO Health app
* Proficient in English language speaking and reading
* Owns their own digital body weighing scale
* Able and willing to provide full informed consent

Exclusion Criteria:

* Prior use of ubiquinol or Co-enzyme Q10 within 3 months of screening
* Diagnosed condition which, in the opinion of the Chief investigator, may independently impact fatigue (e.g. type 1 or type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, inflammatory or autoimmune conditions, cirrhotic or advanced liver disease, malignancy)
* Prior or current use of statin medication
* Has previously used GLP-1 agonists and/or undergone bariatric surgery
* Other medications, which in the opinion of the Chief Investigator, may deplete CoQ10
* Failed screening bloods (any results that is outside of the lab reference range)
* Intention to stop GLP-1 agonist use within 9 months of randomisation
* Pregnancy, breastfeeding or intention to conceive during study

Where it's running

• Office 1110 3 Fitzroy Place, 1/1, Sauchiehall Street
  Glasgow, United Kingdom Recruiting

Study contacts

• Study coordinator: Tom Jameson, PhD
• Email: tom.jameson@studysetgo.com
• Phone: 7794865520

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

  This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.

  Recruiting Yuzuncu Yil University · Van · NCT07901777

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.